Core Viewpoint - The company believes that the recent share buyback reflects management's confidence in the long-term value of the business and aims to enhance market value and shareholder returns [1] Summary by Sections Share Buyback Details - On October 21, 2025, the company repurchased 50,000 shares at a total transaction amount of approximately HKD 1,565,530, with an average price of about HKD 31.31 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 260,000 shares for a total consideration of approximately HKD 8,423,710 [1] Management's Perspective - The board believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as beneficial for the overall interests of the company and its shareholders [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced the repurchase of 50,000 shares at an average price of approximately HKD 31.31 per share, totaling around HKD 1.5655 million [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased a total of 50,000 shares on October 21, 2025, with a total transaction amount of approximately HKD 1.5655 million and an average price of HKD 31.31 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 260,000 shares for a total consideration of approximately HKD 8.4237 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 市場股份回購 本公司欣然公佈，本公司於2025年10月21日於市場購回50,000股本公司股份，總交 易金額約1,565,530港元，交易平均價約每股31.31港元。自2025年10月15日至本公 告日期止期間，本公司已購回共260,000股股份，總對價約8,423,710港元。 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。本 ...

Core Viewpoint - Multiple companies in China conducted share buybacks on October 20, 2025, with notable activity from Mengniu Dairy, which had the largest buyback amount of 10.14 million yuan for 700,000 shares [1][2] Summary by Company - **Mengniu Dairy (02319)**: - Buyback of 700,000 shares - Total buyback amount of 10.14 million yuan - Year-to-date cumulative buyback of 1.92 million shares, representing 0.491% of total share capital [2] - **YunGongChang (N23027)**: - Buyback of 1.87 million shares - Total buyback amount of 7.53 million yuan - Year-to-date cumulative buyback of 2.45 million shares, representing 5.33% of total share capital [2] - **Lianyi Rong Technology (09959)**: - Buyback of 2.45 million shares - Total buyback amount of 7.44 million yuan - Year-to-date cumulative buyback of 6.54 million shares, representing 3.06% of total share capital [2] - **Guoshengtang (02273)**: - Buyback of 232,000 shares - Total buyback amount of 6.83 million yuan - Year-to-date cumulative buyback of 467,810 shares, representing 1.97% of total share capital [2] - **Antong Oilfield Services (03337)**: - Buyback of 4.42 million shares - Total buyback amount of 4.94 million yuan - Year-to-date cumulative buyback of 3.37 million shares, representing 1.14% of total share capital [2] - **Weishi Jiajie (00856)**: - Buyback of 500,000 shares - Total buyback amount of 4.53 million yuan - Year-to-date cumulative buyback of 663,800 shares, representing 0.462% of total share capital [2] - **Beisen Holdings (09669)**: - Buyback of 400,600 shares - Total buyback amount of 3.24 million yuan - Year-to-date cumulative buyback of 143,260 shares, representing 0.204% of total share capital [2] - **Zhongxu Future (09890)**: - Buyback of 228,200 shares - Total buyback amount of 3.13 million yuan - Year-to-date cumulative buyback of 598,580 shares, representing 1.12% of total share capital [2] - **Shoujia Technology (00103)**: - Buyback of 2.8 million shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 5.75 million shares, representing 2.45% of total share capital [2] - **Meili Tianyuan Medical Health (02373)**: - Buyback of 70,000 shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 30,050 shares, representing 0.127% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: - Buyback of 100,000 shares - Total buyback amount of 1.54 million yuan - Year-to-date cumulative buyback of 623,200 shares, representing 7.32% of total share capital [2]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share buyback plan, intending to repurchase 70,000 shares at a cost of HKD 2.2095 million [1] Company Summary - The company plans to execute the buyback on October 20, 2025 [1]

Core Viewpoint - The company announced a strategic acquisition of 100% equity in Shanghai Siyuanli Industrial Co., Ltd. for 1.25 billion RMB, further solidifying its leading position in China's beauty service industry, which is projected to grow significantly in the coming years [1][2]. Group 1: Acquisition Details - The acquisition of Siyuanli, a high-end beauty service brand established in 1996, positions the company among the top three beauty service brands in China, with Siyuanli projected to generate 850 million RMB in revenue and 81 million RMB in net profit in 2024 [1]. - Following the acquisition, the company will hold a market share among the top three brands in the beauty industry, enhancing its competitive advantage, especially in first-tier cities, which contribute nearly 20% of the national beauty service market share [1]. Group 2: Performance Impact - The acquisition is expected to significantly increase the company's performance, with Siyuanli's approximately 60,000 active members being integrated into the group's membership system, leading to a projected 44% year-on-year growth in active members [2]. - The company has a strong track record of improving profitability through mergers and acquisitions, as evidenced by the net profit margin increase of the recently acquired brand Naieryi from 6.5% in 2023 to 10.4% in the first half of 2025 [2]. Group 3: Business Growth - The company's recent anniversary celebration activities showed robust growth, with total rights revenue exceeding 510 million RMB, a year-on-year increase of 13.7%, and net consumption reaching 400 million RMB, up 9.3% year-on-year [2]. - Various business segments, including beauty and health, medical beauty, and healthcare, demonstrated steady growth, with net consumption and customer traffic increasing across the board [2]. Group 4: Profit Forecast - The company has adjusted its profit forecast, expecting net profits of 330 million RMB, 370 million RMB, and 420 million RMB for 2025 to 2027, representing year-on-year growth rates of 43%, 14%, and 11% respectively [3]. - The projected price-to-earnings ratios for 2025, 2026, and 2027 are 21X, 19X, and 17X, respectively, maintaining a "buy" rating based on the anticipated performance growth [3].

Group 1 - The company repurchased 70,000 shares on October 20, 2025, for a total transaction amount of approximately HKD 2.209 million, with an average price of HKD 31.56 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 210,000 shares, with a total consideration of approximately HKD 6.858 million [1]

格隆汇10月20日丨美丽田园医疗健康(02373.HK)公告，10月20日耗资221万港元回购7万股。 ...

Group 1 - The company, 美丽田园医疗健康 (02373), announced a share buyback plan on October 20, 2025, involving an expenditure of HKD 2.2095 million to repurchase 70,000 shares [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share buyback plan, intending to repurchase 70,000 shares at a cost of HKD 2.2095 million, scheduled for October 20, 2025 [1] Company Summary - The company is engaging in a share repurchase, indicating a potential strategy to enhance shareholder value [1] - The total expenditure for the buyback is set at HKD 2.2095 million, reflecting the company's commitment to returning capital to shareholders [1] - The buyback involves 70,000 shares, which may influence the stock's liquidity and market perception [1]